Over time, extensive R&D on the potential health benefits
of cannabis, have enabled medical researchers to identify a number of
pharmacologically active ingredients that offer clinical benefit, minus the
addictive properties of the crude substance. Currently, several stakeholders in
the pharmaceutical industry are actively engaged in the efforts to develop
leads based on natural and synthetic derivatives of cannabinoids.
To order this 250+ page report, which features 140+ figures
and 170+ tables, please visit this
The over USD 5 billion (by 2030)
financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the
following segments:
§
§
§
§
§
§ Route of
Administration
§
§
§ Key
Geographies
§
§
Asia-Pacific and the
Rest of the World
The “Endocannabinoid
System Targeted Therapeutics Market, 2020-2030" report
features the following companies, which we identified to be key players in this
domain:
§ GW
Pharmaceuticals
§ Corbus
Pharmaceuticals
§ Tilray
§ Tetra
Bio-Pharma
§ Botanix
Pharmaceuticals
§ Kalytera
Therapeutics
§ Therapix
Biosciences
§ Echo
Pharmaceuticals
§ Avicanna
§ GB
Sciences
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE: ENDOCANNABINOID
SYSTEM TARGETED THERAPEUTICS
5. COMPANY PROFILES
6. ACADEMIC GRANTS ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. MERGERS AND ACQUISITIONS
9. DRUG DEVELOPMENT STRATEGY ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX
2: LIST OF COMPANIES AND ORGANIZATIONS
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Contact Details
Gaurav
Chaudhary
+1
(415) 800 3415
